Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis

The Role of Cardiac Biomarkers in Cardio-Oncology

(2018) Elizabeth Riddell et al.   CURRENT PROBLEMS IN CANCER

Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

(2018) Mônica Samuel Avila et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer

(2018) Flavia Cochera et al.   Cancer Management and Research

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

(2017) Saro H. Armenian et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced Heart Failure Therapies for Cancer Therapeutics–Related Cardiac Dysfunction

(2017) Christopher M. Bianco et al.   Heart Failure Clinics

Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis

(2016) H Abdel-Qadir et al.   ANNALS OF ONCOLOGY

Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial

(2016) Ahmad Tashakori Beheshti et al.   CARDIOLOGY

Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy

(2016) Ghasem Janbabai et al.   Cardiovascular Toxicology

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

(2016) Geeta Gulati et al.   EUROPEAN HEART JOURNAL

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines

(2016) Jose Luis Zamorano et al.   EUROPEAN HEART JOURNAL

Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO-AML study

(2015) Marianne Jarfelt et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers

(2015) Nausheen Akhter et al.   Future Oncology

Protective effects of spironolactone against anthracycline-induced cardiomyopathy

(2014) Mahmut Akpek et al.   EUROPEAN JOURNAL OF HEART FAILURE

Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron

(2014) Tomáš Šimůnek et al.   Pharmacological Reports

Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up

(2013) Ali Elitok et al.   Cardiology Journal

Abstracts from the XXI World Congress of the International Society for Heart ResearchJune 30-July 4, 20132013, San Diego, California, USA

(2013)   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate

(2013) Mariele Dessì et al.   SpringerPlus

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

(2012) G. Curigliano et al.   ANNALS OF ONCOLOGY

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study

(2012) Mehmet G. Kaya et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial

(2011) Xavier Bosch et al.   JOURNAL OF CARDIAC FAILURE

Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy

(2011) Zeydin Acar et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

(2010) Christian Cadeddu et al.   AMERICAN HEART JOURNAL

Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up

(2010) Peter Georgakopoulos et al.   AMERICAN JOURNAL OF HEMATOLOGY

Anthracycline-Induced Cardiomyopathy

(2010) Daniela Cardinale et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart

(2008) Filomena de Nigris et al.   EUROPEAN JOURNAL OF CANCER